Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

Updated: Jul 26 2022

Pneumocystis jirovecii Pneumonia (PCP)

  • Snapshot
    • A 45-year-old woman presents to the clinic for a nonproductive cough of 2 weeks. She has been feeling increasingly fatigued, weak, and has had low-grade fevers. She reports that she also has shortness of breath with any physical exertion. She smokes 2 cigarettes a day. She has had 10 different sexual partners in the past month and does not use protection reliably. She has a past medical history of diabetes and reports that “something bad” was found on her labs a year ago but that she never followed-up as she had been feeling fine. On physical exam, she has diffused crackles in the lungs. Upon review of her chart, she had a positive HIV test a year ago. She is started on empiric antibiotics.
  • Introduction
    • Classification
      • Pneumocystis jirovecii pneumonia (previously Pneumocysis carinii pneumonia)
        • a yeast-like fungus
        • airborne transmission
    • Associated conditions
      • HIV
    • Prevention
      • smoking cessation
      • prophylaxis with medication
        • trimethoprim-sulfamethoxazole (TMP-SMX)
        • dapsone and pyrimethamine
  • Epidemiology
    • Incidence
      • decreased since the use of prophylaxis in vulnerable populations
      • more common in developing countries
    • Risk factors
      • immunodeficiency
      • HIV
      • malignancy
      • smoking
    • Pathogenesis
      • when both humoral and cellular immunity are suppressed, Pneumocystis attaches to the alveoli
      • activated alveolar macrophages without CD4+ cells are not able to fight the organisms
      • this causes hypoxemia with ↑ alveolar-arterial oxygen gradient and respiratory alkalosis
  • Presentation
    • Symptoms
      • most are asymptomatic in patients with normal immune systems
      • causes interstitial pneumonia in patients with immunosuppression
        • progressive exertional shortness of breath
        • chest pain
        • nonproductive cough
        • fever and chills
        • hemoptysis is rare
    • Physical exam
      • tachypnea, tachycardia, and fever
      • mild crackles and rhonchi in the bilateral lung fields
  • Imaging
    • Chest radiography
      • indication
        • all patients
      • findings
        • bilateral and diffuse infiltrates
    • Computed tomography (CT) of the chest
      • indication
        • if chest radiograph is unclear
      • findings
        • bilateral and diffuse patchy ground-glass opacities
        • pneumatoceles
  • Studies
    • Labs
      • ↑ lactic dehydrogenase
    • Pulmonary function tests
      • ↓ diffusion capacity of carbon monoxide < 75% predicted
      • high sensitivity
    • Histology
      • methenamine silver, Diff-Quik, or Wright stain of lung tissue
        • disc-shaped yeast
    • Making the diagnosis
      • based on lung biopsy or lavage and histology
      • lung tissue histology is needed for a definitive diagnosis
  • Differential
    • Cytomegalovirus (CMV) pneumonia
      • distinguishing factors
        • patients also present with pharyngitis as well as lymphadenopathy and splenomegaly
        • in HIV patients, CMV also involves the gastrointestinal tract
    • Tuberculosis
      • distinguishing factor
        • often presents with hemoptysis
  • Treatment
    • Management approach
      • treatment may be initiated prior to definitive diagnosis
    • Medical
      • trimethoprimsulfamethoxazole (TMP-SMX)
        • indications
          • first-line therapy
          • prophylaxis when CD4+ count < 200 cells/mm3
      • corticosteroids
        • indications
          • in HIV patients with severe cases (arterial-alveolar oxygen gradient > 35 mmHg or PaO2 < 70 mmHg)
          • always given alongside antibiotics
      • pentamidine
        • indication
          • second-line therapy if resistant to TMP-SMX
      • atovaquone
        • indication
          • second-line therapy if resistant to TMP-SMX
      • dapsone and pyrimethamine
        • indication
          • prophylaxis when CD4+ count < 200 cells/mm3
  • Complications
    • Acute respiratory distress syndrome
  • Prognosis
    • Mortality is 10-20%
1 of 0
1 of 7
Private Note

Attach Treatment Poll
Treatment poll is required to gain more useful feedback from members.
Please enter Question Text
Please enter at least 2 unique options
Please enter at least 2 unique options
Please enter at least 2 unique options